Mutations in DNMT3A and TET2 account for approximately 50% of CHIP mutations in people with atherosclerosis, with somatic DNMT3A mutations accounting for roughly 35% of mutations in patients with CHIP and coronary artery disease and early-onset myocardial infarction [33,34]. The gene discussed is DNMT3A; the disease is myocardial infarction.